GSK Partnered Bepirovirsen Achieves Unprecedented Phase 3 Functional Cure Rates for Chronic Hepatitis B

summarizeSummary

Ionis Pharmaceuticals' partner GSK reported highly positive pivotal Phase 3 data for bepirovirsen in chronic hepatitis B, showing significantly higher functional cure rates compared to standard of care.

check_boxKey Events · Product Development and Regulatory · IONS

• Pivotal Phase 3 Success

  Bepirovirsen achieved a 19% functional cure rate in the overall chronic hepatitis B study population and 26% in a key subgroup, significantly outperforming the <1% rate of current standard of care.

• High Royalty Potential

  Ionis is eligible for tiered royalties of 10-12% on net sales of bepirovirsen, in addition to future regulatory and sales milestone payments.

• Advanced Regulatory Status

  The drug holds Breakthrough and Fast Track Designations from the FDA and is under priority review in the U.S., Europe, Japan, and China, with first regulatory decisions expected in Q3 2026.

• Transformative Treatment Potential

  The "unprecedented" functional cure rates suggest bepirovirsen could redefine treatment for chronic hepatitis B, a disease affecting over 240 million people worldwide.

auto_awesomeAnalysis · IONS · Life Sciences

This filing details the successful Phase 3 results for bepirovirsen, a drug licensed to GSK, which demonstrated unprecedented functional cure rates for chronic hepatitis B. The data significantly de-risks this asset, which is already under priority review in multiple major markets. Ionis is eligible for substantial future milestone payments and tiered royalties of 10-12% on net sales, representing a significant long-term revenue opportunity. Regulatory decisions are anticipated in Q3 2026.